BOSTON ( TheStreet) -- The votes for Best and Worst Biotech CEOs of 2014 are counted. Your chosen selections are...
Best Biotech CEOs: David Schenkein of Agios (AGIO) and Nick Leschly of Bluebird Bio (BLUE) .
Congrats, guys, congrats. Applause! Applause!
Schenkein and Leschly (or as I like to refer to them David Leschly and Nick Schenkein) took this year's top honor in runaway style, garnering more than half your votes.
I paired the two CEOs together in this year's Best Biotech CEO poll because their past and present jobs are so intertwined. But individually, they both achieved so much this year. Lechly and his Bluebird team have reinvigorated the field of gene therapy with some amazing, early results -- and potential cures -- in rare blood disorders. At Agios, Schenkein and his crew are exploiting discoveries about the role cellular metabolism plays in disease to develop targeted and highly effective therapies for cancer and other rare disorders.
It's an entirely new field of very promising drug research, and Agios is the clear leader.
Both executives and the companies they lead also ably represent the ascendance of a new age of biotech poised to produce breakthrough treatments for a host of diseases. It's an exciting time to write about biotech and to invest in it, and Schenkein and Leschly are two reasons why.
Here's how the Best Biotech CEO voting shook out:
And now, for the less glamorous award...
The Worst Biotech CEO of 2014: Martin Shkreli, formerly of Retrophin (RTRX) .
On the day he was nominated, Shkreli took to Twitter to defend himself, citing his young age and his accomplishments in starting Retrophin from scratch and growing it quickly into a revenue-generating drug company as reasons he shouldn't have been nominated at all.